EC Backs Nanotechnology with EUR 1 Billion - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EC Backs Nanotechnology with EUR 1 Billion


ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Commission (EC) has made EUR 1 billion available for new projects involving micro and nanotechnology. The amount will come from the EC's Information Communications Technology and Nanoscience, Nanotechnology, Materials and New Production Processes (NMP) funds as part of the Framework Programme 7 (FP7).

"European FP7 enables organizations, through collaborative R&D, to access new partners, skills, and knowledge in the development of their future products and services," Alastair McGibbon, the UK FP7 national contact point for NMP, said in a statement.

The UK's Nanotechnology Knowledge Transfer Network (NanoKTN) is very supportive of the funds, which could provide a boost for the pharmaceutical industry. "Nanotechnology is being increasingly used by the pharmaceutical industry in two areas: drug discovery, where smaller assay volumes are used and greater information is obtained; and formulation, where nanocarriers improve bioavailability and efficacy," Mike Fisher, BioNano Theme Manager at NanoKTN, explained to Pharmaceutical Technology Europe. "Adoption has been relatively slow, but this is because companies need to see a clear path to market."

Several calls for funding have now been scheduled during the next 9 months. The first deadline is Dec. 8, 2009. According to NanoKTN, the UK, as well as the rest of Europe, could stand to benefit from this funding. "Nanotechnologies and microtechnologies are being recognized as important means of wealth and job creation for the UK and Europe, and successful development and uptake of new technology is central to the UK's wealth creation in the next 20 years," Alec Reader, Director of NanoKTN, said in the press statement.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here